The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study

Click to increase image sizeClick to decrease image size

Acknowledgments

The authors thank all co-investigators from the various study sites (a full list of co-investigators is in the Supplementary information) and the patients and families who participated in the trial. Medical writing and editorial support was provided by Simon Wigfield, Caudex, and funded by Bristol Myers Squibb.

Disclosure statement

Joaquín Martínez-López: Grants and advisory boards: Bristol Myers Squibb, Incyte, Janssen; advisory board: Novartis; grants: Roche; Satu Mustjoki: Honoraria and research funding: Bristol Myers Squibb, Novartis, Pfizer; Kimmo Porkka: Research funding: Bristol Myers Squibb, Celgene, Novartis; Rebecca B. Klisovic: Advisory board: Novartis; Dominik Wolf: Honoraria and research funding: Bristol Myers Squibb, Novartis, Pfizer; Lambert Busque: Consultant honoraria: Bristol Myers Squibb, Celgene, Novartis, Pfizer; Juan Carlos Hernández-Boluda: Advisory boards: Incyte, Novartis; Rene Swanink: Employee: Bristol Myers Squibb; Patricia Martin Regueira: Employee: Bristol Myers Squibb; Jeffrey H. Lipton: Research funding and advisory honoraria: Bristol Myers Squibb

Data availability statement

Bristol Myers Squibb policy on data sharing may be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html

Additional information

Funding

This trial was sponsored by Bristol Myers Squibb, Princeton, NJ, USA.